ITCI Intra-Cellular Therapies, Inc. Stock Quote

ITCI [NASD]

Index	-	P/E	-	EPS (ttm)	-3.24	Insider Own	3.40%	Shs Outstand	80.37M	Perf Week	-9.20%
Market Cap	2.46B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-13.78%	Shs Float	76.11M	Perf Month	-16.31%
Income	-227.00M	PEG	-	EPS next Q	-0.80	Inst Own	90.10%	Short Float	8.23%	Perf Quarter	-9.12%
Sales	22.80M	P/S	107.75	EPS this Y	-20.50%	Inst Trans	4.96%	Short Ratio	10.69	Perf Half Y	12.52%
Book/sh	8.17	P/B	3.59	EPS next Y	44.50%	ROA	-37.70%	Target Price	51.63	Perf Year	73.27%
Cash/sh	7.84	P/C	3.74	EPS next 5Y	-	ROE	-41.70%	52W Range	16.14 - 40.01	Perf YTD	-7.86%
Dividend	-	P/FCF	-	EPS past 5Y	-2.10%	ROI	-35.20%	52W High	-26.76%	Beta	1.31
Dividend %	-	Quick Ratio	18.60	Sales past 5Y	201.60%	Gross Margin	91.70%	52W Low	81.54%	ATR	1.64
Employees	383	Current Ratio	18.70	Sales Q/Q	20447.20%	Oper. Margin	-	RSI (14)	35.22	Volatility	5.58% 5.37%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-2.90%	Profit Margin	-	Rel Volume	1.51	Prev Close	30.56
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	Payout	-	Avg Volume	585.87K	Price	29.30
Recom	1.50	SMA20	-8.12%	SMA50	-15.33%	SMA200	4.25%	Volume	882,924	Change	-4.12%

Dec-15-20

Initiated

BofA Securities

Buy

$40

Dec-10-20

Initiated

Goldman

Buy

$38

Feb-20-20

Initiated

Evercore ISI

Outperform

Jan-31-20

Downgrade

JP Morgan

Overweight → Neutral

$26

Dec-24-19

Reiterated

Canaccord Genuity

Buy

$29 → $65

Aug-12-19

Initiated

Jefferies

Buy

$16

Feb-26-18

Initiated

JP Morgan

Overweight

Feb-08-18

Initiated

RBC Capital Mkts

Outperform

$33

Dec-15-17

Initiated

Canaccord Genuity

Buy

$31

Nov-08-17

Upgrade

SunTrust

Hold → Buy

Sep-07-17

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-30-17

Upgrade

Ladenburg Thalmann

Neutral → Buy

Aug-24-17

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

Aug-23-17

Upgrade

Leerink Partners

Mkt Perform → Outperform

May-02-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

May-02-17

Downgrade

Ladenburg Thalmann

Buy → Neutral

May-01-17

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-16-16

Initiated

Cantor Fitzgerald

Overweight

Sep-29-16

Reiterated

RBC Capital Mkts

Outperform

$74 → $49

Sep-29-16

Downgrade

SunTrust

Buy → Neutral

Apr-20-21 07:00AM	Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting GlobeNewswire
Apr-12-21 07:30AM	Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Feb-25-21 08:30PM	Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript Motley Fool -5.71%
07:30AM	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update GlobeNewswire
06:30AM	Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
Feb-24-21 10:42AM	Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes Benzinga
07:30AM	Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284 GlobeNewswire
Feb-22-21 08:00AM	Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression GlobeNewswire
Feb-19-21 08:00AM	Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Feb-17-21 08:00AM	Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast GlobeNewswire
Feb-10-21 02:58AM	Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-21-21 08:00AM	CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research GlobeNewswire
Jan-06-21 08:40AM	Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't? Zacks
Jan-05-21 08:00AM	Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-29-20 08:00AM	Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder GlobeNewswire
Dec-14-20 01:58PM	Intra-Cellular Therapies Getting Closer To Key Technical Benchmark Investor's Business Daily
Dec-09-20 08:00AM	Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire
Dec-01-20 05:32AM	2 Underrated Biotech Stocks to Buy Now Motley Fool
Nov-30-20 08:00AM	Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire -5.36%
Nov-12-20 06:09AM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates Simply Wall St.
Nov-09-20 06:00PM	Intra-Cellular Therapies Inc (ITCI) Q3 2020 Earnings Call Transcript Motley Fool +8.99%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:19AM	Recap: Intra-Cellular Therapies Q3 Earnings Benzinga
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM	Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-20 07:04AM	Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs Motley Fool
Nov-04-20 08:00AM	Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast GlobeNewswire +10.66%
Oct-26-20 08:18AM	Is Intra-Cellular Therapies' (NASDAQ:ITCI) 195% Share Price Increase Well Justified? Simply Wall St.
Oct-04-20 06:20AM	2 Top Biotech Stocks to Buy in October Motley Fool
Oct-02-20 07:00AM	New Ventures Funds Rebrands as Scientia Ventures PR Newswire -7.50%
Oct-01-20 04:30PM	Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer GlobeNewswire
Sep-22-20 11:08AM	Does This Pharma Company's Lead Asset Make it a Buy Today? Motley Fool -5.58%
Sep-15-20 08:00AM	Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Sep-14-20 08:00AM	Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire +10.31%
Sep-11-20 08:42AM	What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)? Simply Wall St. -10.89%
Sep-10-20 08:30PM	Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire
01:38PM	Stick With the Intra-Cellular Rally for Another 25% Upside, Says Analyst TipRanks
Sep-09-20 05:12PM	Nasdaq Soars Nearly 300 Points as Intra-Cellular Breaks Through; a Lemon for Lululemon? Motley Fool +72.87%
04:16PM	Positive Test Results For Bipolar Treatment Sends Intra-Cellular Stock Soaring Investor's Business Daily
04:01PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock GlobeNewswire
12:19PM	Why Intra-Cellular Therapies Stock Is Skyrocketing Today Motley Fool
09:08AM	ROCE Insights For Intra-Cellular Therapies Benzinga
07:00AM	Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression GlobeNewswire
Sep-03-20 08:12AM	Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options Zacks
Aug-10-20 05:30PM	Intra-Cellular Therapies Inc (ITCI) Q2 2020 Earnings Call Transcript Motley Fool -6.93%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:56AM	Recap: Intra-Cellular Therapies Q2 Earnings Benzinga
07:30AM	Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-04-20 11:00AM	Did Hedge Funds Make The Right Call On Intra-Cellular Therapies Inc (ITCI)? Insider Monkey
08:00AM	Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast GlobeNewswire
Jul-28-20 10:30AM	Here's Why We're Not Too Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation Simply Wall St.
Jul-07-20 08:52AM	Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't? Zacks
Jun-29-20 08:00AM	Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure GlobeNewswire
Jun-23-20 09:08PM	Do Hedge Funds Love Intra-Cellular Therapies Inc (ITCI)? Insider Monkey
12:00PM	Intra-Cellular (ITCI) Moves to Buy: Rationale Behind the Upgrade Zacks
Jun-17-20 04:04PM	Neurocrine Adds to Pipeline With $2 Billion Takeda Deal GuruFocus.com
09:43AM	3 Pharmaceutical Stocks With Major Catalysts Approaching TipRanks
Jun-11-20 09:00AM	How Intra-Cellular Therapies (ITCI) Stock Stands Out in a Strong Industry Zacks -7.19%
Jun-04-20 08:49AM	Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options Zacks
May-26-20 11:05AM	Intra-Cellular Therapies' Shares March Higher, Can It Continue? Zacks
May-14-20 08:00AM	Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-13-20 04:15PM	Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders GlobeNewswire -5.52%
May-09-20 09:52AM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
May-08-20 05:00PM	Intra-Cellular Therapies Inc (ITCI) Q1 2020 Earnings Call Transcript Motley Fool +11.09%
May-07-20 11:05AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:30AM	Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Apr-29-20 08:00AM	Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast GlobeNewswire +7.38%
Apr-27-20 09:05AM	How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay? Simply Wall St.
Apr-16-20 04:45PM	Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-07-20 06:12PM	Stocks To Watch: Intra-Cellular Therapies Sees Relative Strength Rating Rise To 93 Investor's Business Daily
05:01PM	Intra-Cellular Therapies Inc (ITCI): Are Hedge Funds Right About This Stock? Insider Monkey
Apr-06-20 11:40PM	Edited Transcript of ITCI earnings conference call or presentation 2-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +7.50%
Apr-02-20 08:00AM	Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults GlobeNewswire
Mar-27-20 10:11AM	Intra-Cellular Therapies (ITCI): Strong Industry, Solid Earnings Estimate Revisions Zacks
Mar-23-20 07:30AM	Intra-Cellular Therapies Announces Availability of CAPLYTA (lumateperone) for Adult Patients with Schizophrenia GlobeNewswire
Mar-02-20 07:30AM	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-25-20 08:45AM	Why Intra-Cellular Therapies (ITCI) Might Surprise This Earnings Season Zacks
Feb-24-20 08:00AM	Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast GlobeNewswire -6.88%
Feb-21-20 04:15PM	Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-20 05:00PM	Pivotal Study of CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry GlobeNewswire
Feb-18-20 10:13AM	What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings? Zacks
08:00AM	Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-27-20 12:31PM	Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Booked A 99% Gain In The Last Year Simply Wall St.
Jan-21-20 08:50AM	Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options Zacks
Jan-10-20 09:04AM	Top Ranked Momentum Stocks to Buy for January 10th Zacks
Jan-08-20 08:12AM	The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results Benzinga -15.03%
Jan-07-20 09:47PM	Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire
07:57AM	The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering Benzinga
Jan-06-20 04:06PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-02-20 08:00AM	Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-19 11:36AM	5 Stocks Financial Advisors Are Looking To Buy This Week Insider Monkey
09:02AM	Moving Average Crossover Alert: Intra-Cellular Therapies Zacks
Dec-24-19 09:04AM	Company News For Dec 24, 2019 Zacks +5.42%
08:13AM	Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI Benzinga
07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
07:06AM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
Dec-23-19 04:15PM	Why This Highflying Biotech Stock Just Rocketed 194% In Massive Volume Investor's Business Daily +193.49%
07:59AM	UPDATE: Intra-Cellular Therapies stock soars 83% premarket after FDA approves schizophrenia treatment MarketWatch
06:59AM	FDA Approves Intra-Cellular Therapies Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults GlobeNewswire
Dec-22-19 12:08PM	The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions Benzinga

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARCUS JOEL S	Director	Mar 02	Option Exercise	26.58	20,000	531,600	87,519	Mar 04 05:43 PM
MARCUS JOEL S	Director	Mar 02	Sale	34.93	15,250	532,682	72,269	Mar 04 05:43 PM
Durgam Suresh K.	Chief Medical Officer	Feb 19	Sale	39.25	2,734	107,310	23,104	Feb 22 08:09 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 19	Sale	39.22	5,184	203,308	45,339	Feb 22 08:07 PM
Hineline Lawrence J.	SVP of Finance CFO	Feb 19	Sale	39.23	10,442	409,625	0	Feb 22 08:05 PM
Halstead Michael	EVP and General Counsel	Feb 19	Sale	39.24	11,139	437,133	0	Feb 22 08:03 PM
Mates Sharon	Chairman, President & CEO	Feb 19	Sale	39.23	27,847	1,092,436	1,133,392	Feb 22 08:01 PM
Durgam Suresh K.	Chief Medical Officer	Jan 11	Sale	32.12	4,367	140,259	17,484	Jan 12 07:07 PM
Neumann Mark	EVP, Chief Commercial Officer	Jan 11	Sale	32.02	9,684	310,082	39,384	Jan 12 07:06 PM
Hineline Lawrence J.	SVP of Finance CFO	Jan 11	Sale	32.02	19,638	628,769	0	Jan 12 07:05 PM
Halstead Michael	EVP and General Counsel	Jan 11	Sale	32.03	19,638	628,978	0	Jan 12 07:03 PM
Mates Sharon	Chairman, President & CEO	Jan 11	Sale	32.01	41,896	1,341,260	1,133,392	Jan 12 07:01 PM
Hineline Lawrence J.	SVP of Finance CFO	Jan 04	Sale	31.31	15,810	495,008	350	Jan 05 06:13 PM
Halstead Michael	EVP and General Counsel	Jan 04	Sale	31.30	16,160	505,834	0	Jan 05 06:11 PM
Mates Sharon	Chairman, President & CEO	Jan 04	Sale	31.30	48,341	1,513,271	1,133,392	Jan 05 06:09 PM
Mates Sharon	Chairman, President & CEO	Dec 18	Option Exercise	2.74	34,000	93,160	1,147,392	Dec 21 04:03 PM
Halstead Michael	EVP and General Counsel	Nov 17	Option Exercise	13.86	75,000	1,039,500	79,425	Nov 19 08:05 PM
Halstead Michael	EVP and General Counsel	Nov 17	Sale	27.62	79,425	2,193,446	0	Nov 19 08:05 PM
Hineline Lawrence J.	SVP of Finance CFO	Nov 11	Option Exercise	3.05	20,000	61,000	28,034	Nov 13 05:51 PM
Hineline Lawrence J.	SVP of Finance CFO	Nov 11	Sale	25.41	28,034	712,344	0	Nov 13 05:51 PM
Mates Sharon	Chairman, President & CEO	Nov 10	Sale	26.34	50,000	1,317,101	1,113,392	Nov 12 05:51 PM
Mates Sharon	Chairman, President & CEO	Nov 04	Sale	25.00	50,000	1,250,000	1,163,392	Nov 06 06:00 PM
Neumann Mark	EVP, Chief Commercial Officer	Oct 16	Sale	26.80	6,792	182,026	28,120	Oct 16 04:04 PM
Alafi Christopher D	Director	Sep 14	Buy	29.60	49,500	1,465,200	4,743,770	Sep 14 05:03 PM
Alafi Christopher D	Director	Sep 11	Buy	28.08	21,000	589,680	4,694,270	Sep 11 04:15 PM
Hineline Lawrence J.	SVP of Finance CFO	Sep 09	Option Exercise	12.73	26,983	343,494	50,017	Sep 11 07:08 PM
Hineline Lawrence J.	SVP of Finance CFO	Sep 09	Sale	31.14	41,983	1,307,351	8,034	Sep 11 07:08 PM
MARCUS JOEL S	Director	May 14	Sale	20.04	9,602	192,424	39,140	May 15 05:37 PM
MARCUS JOEL S	Director	May 13	Sale	20.63	7,297	150,537	14,374	May 13 07:48 PM
LERNER RICHARD A	Director	May 11	Option Exercise	2.74	25,000	68,500	97,313	May 13 05:20 PM
LERNER RICHARD A	Director	May 11	Sale	20.50	3,500	71,750	93,813	May 13 05:20 PM
MARCUS JOEL S	Director	May 11	Sale	19.95	50,000	997,500	48,742	May 13 07:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience